Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 15/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.58 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12811867 | 0.94 | KCNN4 (0.88) | KCNN4KCNE1KCNQ1NPC1RAB9A | |
| SCHEMBL13427555 | 0.83 | KCNN4 (0.71) | KCNN4KCNE1KCNQ1NPC1RAB9A | |
| SCHEMBL12812136 | 0.83 | KCNN4 (0.71) | KCNN4KCNE1KCNQ1NPC1RAB9A | |
| Senicapoc SCHEMBL1443805 | 0.82 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL2337394 | 0.82 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL812971 | 0.81 | KCNN4 (0.76) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL13950934 | 0.81 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL5055356 | 0.80 | KCNN4 (0.67) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL18782553 | 0.78 | KCNN4 (0.72) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL13427600 | 0.78 | KCNN4 (0.63) | KCNN4KCNE1KCNQ1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179115-B2 | Methods for treating malaria using potassium channel inhibitors | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180042872-A1 | METHODS FOR TREATING MALARIA USING POTASSIUM CHANNEL INHIBITORS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180042872-A1 | METHODS FOR TREATING MALARIA USING POTASSIUM CHANNEL INHIBITORS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-02-15 | — | — | US | disclosed |
| WO-2017070536-A1 | METHODS AND AGENTS FOR TREATING DISEASES | ANGION BIOMEDICA CORP. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20070185209-A1 | Treatment methods using triaryl methane compounds | ICAGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185209-A1 | Treatment methods using triaryl methane compounds | ICAGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2007075849-A2 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185209-A1 | Treatment methods using triaryl methane compounds | KCNH3, KCNH2, KCNJ2 | KCNN4 37/4885KCNE1 20/4885KCNQ1 23/4885 |
| US-20180042872-A1 | METHODS FOR TREATING MALARIA USING POTASSIUM CHANNEL INHIBITORS | KCNN1, KCNN2, KCNN3 | KCNN4 10/4885KCNE1 41/4885KCNQ1 5/4885 |
| US-10179115-B2 | Methods for treating malaria using potassium channel inhibitors | KCNN1, KCNN2, KCNN3 | KCNN4 10/4885KCNE1 41/4885KCNQ1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.